Targeted next generation sequencing (NGS) for the detection of drug-resistant TB is a new class of diagnostic technology. It provides an option for rapid and accurate genetic analysis and detection of mutations associated with resistance in a fraction of the time required for culture-based methods for detecting resistance. Various commercially available “End-to-End” tests for targeted NGS have become available in recent years that can detect resistance to multiple drugs simultaneously, provide rapid results with testing directly on patient samples, and have the potential to assimilate new information on genetic markers for resistance as they become known.
“Innovative diagnostic options for people with drug-resistant TB, such as targeted NGS, are increasing thanks to manufacturer engagement and research generating new evidence,” said Dr Tereza Kasaeva, Director of WHO’s Global TB Programme. “Ensuring that everyone in need can obtain a rapid and accurate diagnosis of drug resistant TB will save lives and reduce suffering” Bst DNA polymerase
Detection of all categories of drug-resistant TB remains a challenge and more comprehensive drug susceptibility testing solutions are needed. The introduction of new drugs and repurposing of existing drugs for the treatment of TB and drug-resistant TB have generated new regimens at a rapid rate, improving treatment options, outcomes, and quality of life for individuals with TB. However, as resistance even to these new and repurposed drugs gradually increases, better diagnostic options for rapid diagnosis of drug-resistant TB are needed.
WHO’s Global TB Programme convened a Guideline Development Group meeting between 2-5 May 2023 to review the available evidence on the use of targeted NGS solutions and make recommendations on their clinical use in detecting drug resistant TB.
Bst DNA polymerase The Rapid Communication is released in advance of updated WHO consolidated guidelines for diagnosis of TB, later in 2023, to inform national TB programmes and other stakeholders of key changes expected in the available options for detection of TB drug resistance and to allow for rapid transition and planning at the country level. Further guidance will also be announced soon covering practical information on the steps to introduction of sequencing and the updated catalogue of mutations.